The heart and the liver

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 1, 2009, Pages 51-64

  Møller, Søren ^a,b   Dümcke, Christine Winkler ^b,c   Krag, Aleksander ^a,b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Cardiac cirrhosis; Cardiac failure; Cardiogenic ischemic hepatitis; Cirrhotic cardiomyopathy; Hyperdynamic circulation; Ischemic heart disease; Liver dysfunction; Liver transplantation; Myocardial dysfunction; Portal hypertension; Transjugular intrahepatic portosystemic shunt

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANGIOTENSIN II; ASPARTATE AMINOTRANSFERASE; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILIRUBIN; BRAIN NATRIURETIC PEPTIDE; DOBUTAMINE; GAMMA GLUTAMYLTRANSFERASE; HORMONE PRECURSOR; LACTATE DEHYDROGENASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NORADRENALIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; TERLIPRESSIN; TROPONIN I; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ANGIOCARDIOGRAPHY; ASCITES; CARDIAC CIRRHOSIS; CARDIOGENIC ISCHEMIC HEPATITIS; CARDIOMYOPATHY; CIRRHOTIC CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; ELECTROPHYSIOLOGY; ESOPHAGUS VARICES; EXCITATION CONTRACTION COUPLING; EXERCISE; HEART ARRHYTHMIA; HEART CATHETERIZATION; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HEPATOMEGALY; HUMAN; ISCHEMIC HEART DISEASE; JAUNDICE; LIVER CONGESTION; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION; LIVER INJURY; LIVER PERFUSION; LIVER TRANSPLANTATION; LIVER VEIN PRESSURE; MORTALITY; MYOCARDIAL DISEASE; NONHUMAN; OXYGEN CONSUMPTION; PATHOGENESIS; QT PROLONGATION; REVIEW; SPLENOMEGALY; SYSTOLIC DYSFUNCTION; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; VENOUS PRESSURE; ANIMAL; DISEASE MODEL; ELECTROCARDIOGRAPHY; HEART FAILURE; LIVER CIRRHOSIS; PATHOPHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; ELECTROCARDIOGRAPHY; HEART DISEASES; HEART FAILURE; HEMODYNAMICS; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES;

EID: 65549123307     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.3.1.51     Document Type: Review

References (139)

1. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennecs cirrhosis. J. Clin, Invest. 32, 1025-1033 (1953).
2. Møller S, Henriksen JH. The systemic circulation in cirrhosis. In: Ascites and Renal Dysfunction in Liver Disease (2nd Edition). Gines P, Arroyo V, Rodes J, Schrier RW (Eds). Blackwell, MA, USA, 139-155 (2005).
3. Schrier RW. Decreased effective blood volume in edematous disorders: what does this mean? J. Am. Soc. Nephrol. 18, 2028-2031 (2007).
4. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 43, S121-S131 (2006).
5. Alqahtani SA, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Semin. Liver Dis. 28, 59-69 (2008).
6. Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J. Hepatol. 44, 994-1002 (2006).
7. Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 57, 268-278 (2008).
8. Mohamed R, Forsey PR, Davies MK, Neuberger JM. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 23, 1128-1134 (1996).
9. Cazzaniga M, Salerno F, Pagnozzi G et al. Diastolic dysfunction is associated with poor survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Gut 56, 869-875 (2007).
10. Torregrosa M, Aguade S, Dos L et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J. Hepatol. 42, 68-74 (2005).
11. Blei AT, Mazhar S, Davidson CJ, Flamm SL, Abecassis M, Gheorghiade M. Hemodynamic evaluation before liver transplantation: insights into the portal hypertensive syndrome. J. Clin. Gastroenterol. 41, S323-S329 (2007).
12. Kubo SH, Walter BA, John DH, Clark M, Cody RJ. Liver function abnormalities in chronic heart failure. Influence of systemic hemodynamics. Arch. Intern. Med. 147, 1227-1230 (1987).
13. Naschitz JE, Slobodin G, Lewis RJ, Zuckerman E, Yeshurun D. Heart diseases affecting the liver and liver diseases affecting the heart. Am. Heart J. 140, 111-120. (2000).
14. Dunn GD, Hayes P, Breen KJ, Schenker S. The liver in congestive heart failure: a review. Am. J. Med. Sci. 265, 174-189 (1973).
15. Henrion J, Schapira M, Luwaert R, Colin L, Delannoy A, Heller FR. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 82, 392-406 (2003).
16. Batin P, Wickens M, McEntegart D, Fullwood L, Cowley AJ. The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur. Heart J. 16, 1613-1618 (1995).
17. Crespo-Leiro MG, Robles O, Paniagua MJ et al. Reversal of cardiac cirrhosis following orthotopic heart transplantation. Am. J. Transplant., 1336-1339 (2008).
18. Tiukinhoy-Laing SD, Blei AT, Gheorghiade M. The liver in cardiovascular disease. In: Textbook of Hepatology: from Basic Science to Clinical Practice. Rodes J, Benhamou JP, Blei AT, Reichen J, Rizzetto M (Eds). Blackwell, NY, USA, 1609-1615 (2007).
19. Schrier RW, Ecder T. Unifying hypothesis of body fluid volume regulation: implications for cardiac failure and cirrhosis. Mt Sinai J. Med. 68, 350-361 (2001).
20. Schrier RW. Vasopressin and aquaporin 2 in clinical disorders of water homeostasis. Semin. Nephrol. 28, 289-296 (2008).
21. Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am. J. Med. 109, 109-113 (2000).
22. Hickman PE, Potter JM. Mortality associated with ischaemic hepatitis. Aust. NZ J. Med. 20, 32-34 (1990).
23. Cassidy WM, Reynolds TB. Serum lactic dehydrogenase in the differential diagnosis of acute hepatocellular injury. J. Clin. Gastroenterol. 19, 118-121 (1994).
24. Lunzer MR, Manghani KK, Newman SP, Sherlock S, Bernard AG, Ginsberg J. Impaired cardiovascular responsiveness in liver disease. Lancet 2, 382-385 (1975).
25. Bomzon A. Impaired responsiveness to angiotensin II in experimental cirrhosis. Hepatology 20, 266-267 (1994).
26. Bomzon A, Blendis LM. The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis. Hepatology 20, 1343-1350 (1994).
27. Castro A, Jimenez W, Claria J et al. Impaired responsiveness to angiotensin-II in experimental cirrhosis - role of nitric oxide. Hepatology 18, 367-372 (1993).
28. Polio J, Sieber CC, Lerner E, Groszmann RJ. Cardiovascular hyporesponsiveness to norepinephrine, propranolol and nitroglycerin in portal-hypertensive and aged rats. Hepatology 18, 128-136 (1993).
29. Hennenberg M, Trebicka J, Sauerbruch T, Heller J. Mechanisms of extrahepatic vasodilation in portal hypertension. Gut 57, 1300-1314 (2008).
30. Helmy A, Newby DE, Jalan R, Johnston NR, Hayes PC, Webb DJ. Nitric oxide mediates the reduced vasoconstrictor response to arrgiotensin II in patients with preascitic cirrhosis. J. Hepatol. 38, 44-50 (2003).
31. Ingles AC, Hernandez I, Garcia-Estan J, Quesada T, Carbonell LF. Limited cardiac preload reserve in conscious cirrhotic rats. Am. J. Physiol. 260, H1912-H1917 (1991).
32. 2-adrenoceptors in cirrhotic patients with severe ascites. Lancet 1, 1409-1411 (1986).
33. Lee SS, Marty J, Mantz J, Samain E, Braillon A, Lebrec D. Desensitization of myocardial β-adrenergic receptors in cirrhotic rats. Hepatology 12, 481-485 (1990).
34. Ma Z, Meddings JB, Lee SS. Membrane physical properties determine cardiac β-adrenergic receptor function in cirrhotic rats. Am. J. Physiol. 267, G87-G93 (1994).
35. Ma Z, Miyamoto A, Lee SS. Role of altered β-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology 110, 1191-1198 (1996).
36. Ma Z, Lee SS, Meddings JB. Effects of altered cardiac membrane fluidity on β-adrenergic receptor signalling in rats with cirrhotic cardiomyopathy. J. Hepatol. 26, 904-912 (1997).
37. Ceolotto G, Papparella I, Sticca A et al. An abnormal gene expression of the β-adrenergic system contributes to the pathogenesis of cardiomyopathy in cirrhotic rats. Hepatology 48(6), 1913-1923 (2008).
38. Ward CA, Liu H, Lee SS. Altered cellular calcium regulatory systems in a rat model of cirrhotic cardiomyopathy. Gastroenterology 121, 1209-1218 (2001).
39. Zavecz JH, Bueno O, Maloney RE, O'Donnell JM, Roerig SC, Battarbee HD. Cardiac excitation-contraction coupling in the portal hypertensive rat. Am. J. Physiol. Gastrointest. Liver Physiol. 279, G28-G39 (2000).
40. Jaue DN, Ma ZH, Lee SS. Cardiac muscarinic receptor function in rats with cirrhotic cardiomyopathy. Hepatology 25, 1361-1365 (1997).
41. Ward CA, Ma Z, Lee SS, Giles WR. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am. J. Physiol. 273, G537-G544 (1997).
42. Tavakoli S, Hajrasouliha AR, Jabehdar-Maralani P et al. Reduced susceptibility to epinephrine-induced arrhythmias in cirrhotic rats: the roles of nitric oxide and endogenous opioid peptides. J. Hepatol. 46, 432-439 (2007).
43. Van Obbergh L, Vallieres Y, Blaise G. Cardiac modifications occurring in the ascitic rat with biliary cirrhosis are nitric oxide related. J. Hepatol. 24, 747-752 (1996).
44. Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology 118, 937-944 (2000).
45. Inserte J, Perello A, Agullo L et al. Left ventricular hypertrophy in rats with biliary cirrhosis. Hepatology 38, 589-598 (2003).
46. Mani AR, Ippolito S, Ollosson R, Moore KP. Nitration of cardiac proteins is associated with abnormal cardiac chronotropic responses in rats with biliary cirrhosis. Hepatology 43(4), 847-856 (2006).
47. Liu H, Song D, Lee SS. Role of heme oxygenase-carbon monoxide pathway in pathogenesis of cirrhotic cardiomyopathy in the rat. Am. J. Physiol. Gastrointest. Liver Physiol. 280, G68-G74 (2001).
48. Garcia-Estan J, Ortiz MC, Lee SS. Nitric oxide and renal and cardiac dysfunction in cirrhosis. Clin. Sci. (Lond.) 102, 213-222 (2002),
49. Liu H, Lee SS. Nuclear factor-κB inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy. Liver Int. 28(5), 640-648 (2008).
50. Siegmund SV, Uchinami H, Osawa Y, Brenner DA, Schwabe RF. Anandamide induces necrosis in primary hepatic stellate cells. Hepatology 41, 1085-1095 (2005).
51. Liu H, Gaskari SA, Lee SS. Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J. Gastroenterol. 12, 837-842 (2006).
52. Gaskari SA, Liu H, Moezi L, Li Y, Baik SK, Lee SS. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br. J. Pharmacol. 146(3), 315-323 (2005).
53. 1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am. J. Physiol. Heart Circ. Physiol. 293(3), H1689-H1695 (2007).
54. Keller H, Bezjak V, Stegaru B, Buss J, Holm E, Heene DL. Ventricular function in cirrhosis and portasystemic shunt: a two-dimensional echocardiographic study. Hepatology 8, 658-662 (1988).
55. Ahmed SS, Howard M, Hove WT, Leevy CM, Regan TJ. Cardiac function in alcoholics with cirrhosis: absence of overt cardiomyopathy - myth or fact? J. Am. Coll. Cardiol. 3(3), 696-702 (1984).
56. Gould L, Shariff M, Zahir M. Cardiac hemodynamics in alcoholic patients with chronic liver disease and a presystolic gallop. J. Clin. Invest 48, 860-864 (1969).
57. Møller S, Henriksen JH. Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand. J. Gastroenterol. 36, 785-794 (2001).
58. Kelbæk H, Eriksen J, Brynjolf I et al. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am. J. Cardiol. 54, 852-855 (1984).
59. Kelbæk H, Rabøl A, Brynjolf I et al. Haemodynamic response to exercise in patients with alcoholic liver cirrhosis. Clin. Physiol. 7, 35-41 (1987).
60. Bernardi M, Rubboli A, Trevisani F et al. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. J. Hepatol. 12, 207-216 (1991).
61. Limas CJ, Guiha NH, Lekagul O. Impaired left ventricular function in alcoholic cirrhosis with ascites. J. Lab. Clin. Med. 89, 1175-1187 (1977).
62. Mikulic E, Munoz C, Puntoni LE, Lebrec D. Hemodynamic effects of dobutamine in patients with alcoholic cirrhosis. Clin. Pharmacol. Ther. 34, 56-59 (1983).
63. Donovan CL, Marcovitz PA, Punch JD et al. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation 61, 1180-1188 (1996).
64. Krag A, Bendtsen F, Henriksen JH, Møller S. Cardiac effects of terlipressin in cirrhosis. Unmasking a cirrhotic cardiomyopathy. J. Hepatol. 46, S96 (2007) (Abstract 252).
65. Møller S, Søndergaard L, Møgelvang J, Henriksen O, Henriksen JH. Decreased right-sided heart blood volume determined by magnetic resonance imaging: evidence of central underfilling in cirrhosis. Hepatology 22, 472-478 (1995),
66. Finucci G, Desideri A, Sacerdoti D et al. Left ventricular diastolic function in liver cirrhosis. Scand. J. Gastroenterol. 31, 279-284 (1996).
67. Valeriano V, Funaro S, Lionetti R et al. Modification of cardiac function in cirrhotic patients with and without ascites. Am. J. Gastroenterol. 95, 3200-3205 (2000).
68. Epstein SK, Ciubotaru RL, Zilberberg MD et al. Analysis of impaired exercise capacity in patients with cirrhosis. Dig. Dis. Sci. 43, 1701-1707 (1998).
69. Grose RD, Nolan J, Dillon JF et al. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J. Hepatol. 22, 326-332 (1995).
70. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut 49, 268-275 (2001).
71. Bernardi M, Domenicali M. The renin-angiotensin-aldosterone system in cirrhosis. In: Ascites and Renal Dysfunction in Liver Fisease (2nd Edition). Ginés P, Arroyo V, Rodes J, Schrier RW (Eds). Blackwell, MA, USA, 43-54 (2005).
72. Ruiz-Del-Arbol L, Monescillo A, Arocena C et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 42, 439-447 (2005).
73. Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac index predicts survival and renal failure in patients with ascites. Evidence of a heart-kidney axis in cirrhosis. J. Hepatol. 48, S118 (2008) (Abstract 295).
74. Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin. Sci. 97, 259-267 (1999).
75. Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 24, 451-459 (1996).
76. Pozzi M, Carugo S, Boari G et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 26, 1131-1137 (1997).
77. Huonker M, Schumacher YO, Ochs A, Sorichter S, Keul J, Rǒssle M. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 44, 743-748 (1999).
78. Merli M, Valeriano V, Funaro S et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am. J. Gastroenterol. 97, 142-148 (2002).
79. Alexander J, Mishra P, Desai N, Ambadekar S, Gala B, Sawant P. Cirrhotic cardiomyopathy: Indian scenario. J. Gastroenterol. Hepatol. 22, 395-399 (2007).
80. Therapondos G, Flapan AD, Dollinger MM, Garden OJ, Plevris JN, Hayes PC. Cardiac function after orthotopic liver transplantation and the effects of immunosuppression: a prospective randomized trial comparing cyclosporin (Neoral) and tacrolimus. Liver Transpl. 8, 690-700 (2002).
81. Pozzi M, Redaelli E, Ratti L et al. Time-course of diastolic dysfunction in different stages of chronic HCV related liver diseases. Minerva Gastroenterol. Dietol. 51, 179-186 (2005).
82. Pateron D, Beyne P, Laperche T et al. Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology 29, 640-643 (1999).
83. Gerbes AL, Wernze H, Arendt RM, Riedel A, Sauerbruch T, Paumgartner G. Atrial natriuretic factor and renin-aldosterone in volume regulation of patients with cirrhosis. Hepatology 9, 417-422 (1989).
84. Rector WG Jr, Adair O, Hossack KF, Rainquet S. Atrial volume in cirrhosis: relationship to blood volume and plasma concentrations of atrial natriuretic factor. Gastroenterology 99, 766-770 (1990).
85. De BK, Majumdar D, Das D et al. Cardiac dysfunction in portal hypertension among patients with cirrhosis and non-cirrhotic portal fibrosis. J. Hepatol. 39, 315-319 (2003).
86. Iwao T, Oho K, Nakano R et al. High plasma cardiac natriuretic peptides associated with enhanced cyclic guanosine monophosphate production in preascitic cirrhosis. J. Hepatol. 32, 426-433 (2000).
87. Wong F, Siu S, Liu P, Blendis LM. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? Clin. Sci. (Lond.) 101, 621-628 (2001).
88. Henriksen JH, Gotze JP, Fuglsang S, Christensen E, Bendtsen F, Møller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 52, 1511-1517 (2003).
89. Yildiz R, Tildirim B, Karincaoglu M, Harputluoglu M, Hilmioglu F. Brain natriuretic peptide and severity of disease in non-alcoholic cirrhotic patients. J. Gastroenterol. Hepatol. 20, 1115-1120 (2005).
90. Day PC, James FWO, Butler JT, Campbell RWF. Q-T prolongation and sudden, cardiac death in patients with alcoholic liver disease. Lancet 341, 1423-1428 (1993).
91. Kempler P, Varadi A, Kadar E, Szalay F. Autonomic and peripheral neuropathy in primary biliary cirrhosis: evidence of small sensory fibre damage and prolongation of the QT interval. J. Hepatol. 21, 1150-1151 (1994).
92. Lazzeri C, Lavilla G, Laffi G et al. Autonomic regulation of heart rate and QT interval in nonalcoholic cirrhosis with ascites. Digestion 58, 580-586 (1997).
93. Garcia GM, Hernandez-Madrid A, Lopez-Sanroman A, Candela A, Nuno J, Barcena R. Reversal of QT interval electrocardiographic alterations in cirrhotic patients undergoing liver transplantation. Transplant. Proc. 31, 2366-2367 (1999).
94. Puthumana L, Chaudhry V, Thuluvath PJ. Prolonged QTc interval and its relationship to autonomic cardiovascular reflexes in patients with cirrhosis. J. Hepatol. 35, 733-738 (2001).
95. Carey EJ, Douglas DD. Effects of orthotopic liver transplantation on the corrected QT interval in patients with end-stage liver disease. Dig. Dis. Sci. 50, 320-323 (2005).
96. Adigun AQ, Pinto AG, Flockhart DA et al. Effect of cirrhosis and liver transplantation on the gender difference in QT interval. Am. J. Cardiol. 95, 691-694 (2005).
97. Bernardi M, Calandra S, Colantoni A et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 27, 28-34 (1998).
98. Bal JS, Thuluvath PJ. Prolongation of QTc interval; relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver Int. 23, 243-248 (2003).
99. Trevisani F, Merli M, Savelli F et al. QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J. Hepatol. 38, 461-467 (2003).
100. Ytting H, Henriksen JH, Fuglsang S, Bendtsen F, Møller S. Prolonged Q-T(c) interval in mild portal hypertensive cirrhosis. J. Hepatol. 43, 637-644 (2005).
101. Henriksen JH, Bendtsen F, Hansen EF, Møller S, Acute non-selective β-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis. J. Hepatol. 40, 239-246 (2004).
102. Zambruni A, Trevisani F, Di Micoli A et al. Effect of chronic β-blockade on QT interval in patients with liver cirrhosis. J. Hepatol. 48, 415-421 (2008).
103. Hansen S, Moller S, Bendtsen F, Jensen G, Henriksen JH. Diurnal variation and dispersion in QT interval in cirrhosis: relation to haemodynamic changes. J. Hepatol. 47, 373-380 (2007).
104. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Møller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J. Hepatol. 36, 513-520 (2002).
105. Laffi G, Lagi A, Cipriani M et al. Impaired cardiovascular autonomic response to passive tilting in cirrhosis with ascites. Hepatology 24, 1063-1067 (1996).
106. Veglio F, Melchio R, Calva S et al. Noninvasive assessment of spontaneous baroreflex sensitivity in patients with liver cirrhosis. Liver 18, 420-426 (1998).
107. Dumcke CW, Møller S. Autonomic dysfunction in cirrhosis and portal hypertension. Scand. J. Clin. Lab. Invest. 68(6), 437-447(2008).
108. Møller S, Iversen JS, Henriksen JH, Bendtsen F. Reduced baroreflex sensitivity in alcoholic cirrhosis: relations to hemodynamics and humoral systems to Am. J. Physiol. Heart Circ. Physiol. 292, H2966-H2972 (2007).
109. Azoulay D, Castaing D, Dennison A, Martino W, Eyraud D, Bismuth H. Transjugular intrahepatic portosystemic shunt worsens the hyperdynamic circulatory state of the cirrhotic patient - preliminary report of a prospective study. Hepatology 19, 129-132 (1994).
110. Quiroga J, Sangro B, Nunez M et al. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology 21, 986-994 (1995).
111. Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L. Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann. Intern. Med. 122, 816-822 (1995).
112. Braverman AC, Steiner MA, Picus D, White H. High-output congestive heart failure following transjugular intrahepatic portal-systemic shunting. Chest 107, 1467-1469 (1995).
113. Rodriguezlaiz JM, Banares R, Echenagusia A et al. Effects of transjugular intrahepatic portasystemic shunt (TIPS) on splanchnic and systemic hemodynamics, and hepatic function in patients with portal hypertension: preliminary results. Dig. Dis. Sci. 40, 2121-2127 (1995).
114. Schwartz JM, Beymer C, Althaus SJ et al. Cardiopulmonary consequences of transjugular intrahepatic portosystemic shunts: role of increased pulmonary artery pressure. J. Clin. Gastroenterol. 38, 590-594 (2004).
115. Gines P, Uriz J, Calahorra B et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 123, 1839-1847 (2002).
116. Colombato LA, Spahr L, Martinet JP et al. Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients. Gut 39, 600-604 (1996).
117. Vanderlinden P, Lemoine O, Ghysels M, Ortinez M, Deviere J. Pulmonary hypertension after transjugular intrahepatic portosystemic shunt: effects on right ventricular function. Hepatology 23, 982-987 (1996).
118. Lotterer E, Wengert A, Fleig WE. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis. Hepatology 29, 632-639 (1999).
119. Henderson JM, Mackay GJ, Hooks M et al. High cardiac output of advanced liver diseases persists after orthotopic liver transplantation. Hepatology 15, 258-262 (1992).
120. Navasa M, Feu F, Garciapagan JC et al. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology 17, 355-360 (1993).
121. Piscaglia F, Zironi G, Gaiani S et al. Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. Hepatology 30, 58-64 (1999).
122. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl. 6, S44-S52 (2000).
123. Ripoll C, Catalina MV, Yotti R et al. Cardiac dysfunction during liver transplantation: incidence and preoperative predictors. Transplantation 85, 1766-1772 (2008).
124. Gadano A, Hadengue A, Widmann JJ et al. Hemodynamics after orthotopic liver transplantation: study of associated factors and long-term effects. Hepatology 22, 458-465 (1995).
125. Carey EJ, Gautam M, Ingall T, Douglas DD. The effect of liver transplantation on autonomic dysfunction in patients with end-stage liver disease. Liver Transpl. 14, 235-239 (2008).
126. Keeffe BG, Valantine H, Keeffe EB. Detection and treatment of coronary artery disease in liver transplant candidates. Liver Transpl. 7, 755-761 (2001).
127. Plotkin JS, Scott VL, Pinna A, Dobsch BP, De Wolf AM, Kang Y. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl. Surg. 2, 426-430 (1996).
128. Tiukinhoy-Laing SD, Rossi JS, Bayram M et al. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am. J. Cardiol. 98, 178-181 (2006).
129. Burra P, Graziotto A, Senzolo M et al. Myocardial perfusion scintigraphy in patients with liver cirrhosis evaluated for orthotopic liver transplantation. Transplant. Proc. 33, 1447-1448 (2001).
130. Henriksen JH, Fuglsang S, Bendtsen F, Møller S. Arterial hypertension in cirrhosis: arterial compliance, volume distribution, and central haemodynamics. Gut 55(3), 380-387 (2006).
131. Solaymani-Dodaran M, Aithal GP, Card T, West J. Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study. Am. J. Gastroenterol. 103(11), 2784-2788 (2008).
132. Davidson CJ, Gheorghiade M, Flaherty JD et al. Predictive value of stress myocardial perfusion imaging in liver transplant candidates. Am. J. Cardiol. 89, 359-360 (2002).
133. Mori T, Nomura M, Hori A, Kondo N, Bando S, Ito S. Mechanism of ST segment depression during exercise tests in patients with liver cirrhosis. J. Med. Invest. 54, 109-115 (2007).
134. Senzolo M, Bassanello M, Graziotto A et al. Microvascular autonomic dysfunction may justify false-positive stress myocardial perfusion imaging in patients with liver cirrhosis undergoing liver transplantation. Transplant. Proc. 40, 1916-1917 (2008).
135. Mandell MS, Lindenfeld J, Tsou MY, Zimmerman M, Cardiac evaluation of liver transplant candidates. World J. Gastroenterol. 14, 3445-3451 (2008).
136. Bellentani S, Bedogni G, Tiribelli C. Liver and heart: a new link?. J. Hepatol. 49, 300-302 (2008).
137. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 51(11), 1947-1953 (2008).
138. Pozzi M, Grassi G, Ratti L et al. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. Am. J. Gastroenterol. 100, 1110-1116 (2005).
139. Neubauer S. The failing heart - an engine out of fuel. N. Engl. J. Med. 356, 1140-1151 (2007).